Small-Molecule PARG Inhibitors for Selective Tyr795 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PARG inhibitors, such as Gallotannin and quinazolinedione sulfonamide derivatives, exhibit nonspecific modes of action, membrane permeability issues, and rapid clearance in vivo, limiting their effectiveness as therapeutic agents for cancer treatment.
Innovation Solution
Development of small molecule PARG inhibitors that selectively target the adenine-binding pocket of PARG, causing specific displacements of Tyr795 and Arg671, and form n-stacking interactions with Phe902, with IC50 activity below 0.5 μM, to inhibit PARG activity without significantly affecting PARP1 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Gallotannin is used as a PARG inhibitor, then PARG inhibition activity is achieved, but membrane permeability and specificity are compromised
Solution Approach 1:
The patent modifies the chemical structure of Gallotannin by changing parameters such as molecular size, functional groups, and stereochemistry to create derivatives with improved membrane permeability and specificity for PARG, while retaining the core inhibition mechanism
Solution Approach 2:
The invention introduces specific local modifications to the Gallotannin structure, such as adding or modifying particular functional groups at specific positions, to enhance binding affinity for PARG while reducing nonspecific interactions with other cellular components
2Reliability
If quinazolinedione sulfonamide derivatives are used as PARG inhibitors, then PARG inhibition is achieved, but in vivo clearance is rapid
Solution Approach 1:
The patent modifies physical-chemical parameters of the quinazolinedione sulfonamide derivatives, such as lipophilicity, molecular weight, and metabolic stability, to reduce rapid clearance in vivo while maintaining potent PARG inhibition activity
Solution Approach 2:
The invention creates composite molecular structures combining the quinazolinedione sulfonamide core with additional moieties that improve pharmacokinetic properties, such as increased plasma protein binding or reduced renal clearance, thereby extending in vivo duration of action
3Reliability
If small molecule PARG inhibitors are designed to target adenine-binding pocket, then selectivity is improved, but molecular design complexity increases
Solution Approach 1:
The patent employs structure-based drug design by copying the adenine moiety's binding interactions with the PARG adenine-binding pocket, using analogs and derivatives that replicate key binding features while simplifying overall molecular complexity
Solution Approach 2:
The invention divides the inhibitor molecule into distinct functional segments: a core adenine-like binding unit that targets the adenine-binding pocket, and separate pharmacophoric elements that provide selectivity, allowing systematic optimization of each segment independently
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The small molecule PARG inhibitors provide selective and potent inhibition of PARG, enhancing cancer treatment efficacy by modulating PARylation reversal, particularly in BRCA-deficient breast cancer cells, while minimizing off-target effects.
Implementation Method 1
form n-stacking interactions with Phe902
Data Source
AI summary
The present disclosure provides methods of inhibiting PARG in cancer cells, including methods comprising administering a PARG inhibitor that modulates position Tyr795 in PARG. Also provided herein are methods of treating and/or preventing cancer comprising administering a PARG inhibitor. In some embodiments, the PARG inhibitors are of the formula: wherein the variables are defined herein.